The growth in the historic period can be attributed to low compliance with three dose vaccines, rising hepatitis b burden in adults, early adoption in healthcare worker immunization, demand for improved vaccine efficacy, increasing awareness of adult immunization.
The growth in the forecast period can be attributed to expansion of adult vaccination mandates, increasing focus on diabetic and liver disease patients, wider adoption by integrated delivery networks, growth in employer sponsored vaccination programs, continued emphasis on preventive healthcare. Major trends in the forecast period include two dose adult hepatitis b vaccination adoption, rising preference for high seroprotection vaccines, growth in vaccination among high risk adult populations, shift toward convenience driven immunization schedules, expansion of workplace and occupational vaccination programs.
The growing prevalence of hepatitis B infections is anticipated to drive the expansion of the Heplisav-B market in the coming years. Hepatitis B infections are liver diseases caused by the hepatitis B virus (HBV), which can lead to both acute and chronic conditions, such as cirrhosis and liver cancer. The increasing prevalence of hepatitis B is attributed to factors like low vaccination rates, high-risk group transmission, limited awareness, and insufficient healthcare access. Heplisav-B is a vaccine designed to prevent hepatitis B infection by stimulating the immune system to produce protective antibodies. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported 2,214 new cases of acute hepatitis B in 2023, along with 1,769 hepatitis B-related deaths. As a result, the rising prevalence of hepatitis B infections is expected to accelerate the growth of the Heplisav-B market.
The increasing prevalence of chronic diseases is also expected to contribute to the growth of the Heplisav-B market in the future. Chronic diseases are long-term health conditions that develop gradually, persist over an extended period, and often require continuous medical care and lifestyle management. The rise in chronic diseases is driven by factors such as aging populations, lifestyle changes, inadequate healthcare access, and heightened environmental exposures. Heplisav-B is particularly important in managing chronic diseases, especially for individuals with weakened immune systems, as it provides a stronger and longer-lasting immune response against hepatitis B. For instance, in June 2024, the National Health Service (NHS), a U.K.-based government department, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is expected to support the growth of the Heplisav-B market.
A key trend in the Heplisav-B market is the development of innovative products, such as hepatitis B adjuvanted vaccines, aimed at providing stronger and longer-lasting immune responses. A hepatitis B adjuvanted vaccine includes an adjuvant that enhances the body’s immune response to the hepatitis B surface antigen, thereby improving the vaccine's efficacy, particularly in populations with weaker immune systems. For instance, in February 2023, Dynavax Technologies Corporation, a U.S.-based biopharmaceutical company, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Heplisav-B for marketing in Great Britain. This vaccine is intended for adults and is approved for active immunization against all known subtypes of the hepatitis B virus (HBV) in individuals aged 18 years and older. The approval was based on favorable safety and immunogenicity outcomes from three Phase 3 clinical trials. Heplisav-B combines the hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist adjuvant, CpG 1018, to enhance the immune response. Dynavax holds the global commercial rights to Heplisav-B.
Major companies operating in the heplisav-b market are Dynavax Technologies Corporation.
North America was the largest region in the heplisav-B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heplisav-b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heplisav-b market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the heplisav-b market by increasing costs associated with vaccine raw materials, adjuvant components, and specialized manufacturing equipment. These impacts are most evident in hospital procurement and large clinic vaccination programs, particularly in regions reliant on imported vaccine inputs. Higher tariffs may affect pricing negotiations and vaccine accessibility in some markets. However, tariffs are also encouraging domestic vaccine production and localized supply chains. This is supporting long term resilience and supply stability in adult immunization programs.
The heplisav-b market research report is one of a series of new reports that provides heplisav-b market statistics, including heplisav-b industry global market size, regional shares, competitors with a heplisav-b market share, detailed heplisav-b market segments, market trends and opportunities, and any further data you may need to thrive in the heplisav-b industry. This heplisav-b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Heplisav-B is a recombinant vaccine developed to protect adults aged 18 and older against hepatitis B. It contains hepatitis B surface antigen (HBsAg) along with an advanced adjuvant (1018) to boost the immune response. Given as a two-dose series within a month, Heplisav-B provides higher seroprotection rates and greater convenience than traditional three-dose vaccines, making it especially beneficial for high-risk individuals, including healthcare workers, those with chronic liver disease, or individuals with diabetes.
The primary types of Heplisav-B products include vaccines and combination vaccines. Vaccines are biological substances that offer immunity against specific infectious diseases by stimulating the immune system to recognize and combat pathogens. It is used for adult hepatitis B prevention, as well as for special populations, and is distributed through integrated delivery networks (IDNs), large clinics, retail pharmacies, and hospitals.
The heplisav-B market consists of sales of adjuvants, immunology products, diagnostic kits, and therapeutic vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of adult vaccination mandates, increasing focus on diabetic and liver disease patients, wider adoption by integrated delivery networks, growth in employer sponsored vaccination programs, continued emphasis on preventive healthcare. Major trends in the forecast period include two dose adult hepatitis b vaccination adoption, rising preference for high seroprotection vaccines, growth in vaccination among high risk adult populations, shift toward convenience driven immunization schedules, expansion of workplace and occupational vaccination programs.
The growing prevalence of hepatitis B infections is anticipated to drive the expansion of the Heplisav-B market in the coming years. Hepatitis B infections are liver diseases caused by the hepatitis B virus (HBV), which can lead to both acute and chronic conditions, such as cirrhosis and liver cancer. The increasing prevalence of hepatitis B is attributed to factors like low vaccination rates, high-risk group transmission, limited awareness, and insufficient healthcare access. Heplisav-B is a vaccine designed to prevent hepatitis B infection by stimulating the immune system to produce protective antibodies. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported 2,214 new cases of acute hepatitis B in 2023, along with 1,769 hepatitis B-related deaths. As a result, the rising prevalence of hepatitis B infections is expected to accelerate the growth of the Heplisav-B market.
The increasing prevalence of chronic diseases is also expected to contribute to the growth of the Heplisav-B market in the future. Chronic diseases are long-term health conditions that develop gradually, persist over an extended period, and often require continuous medical care and lifestyle management. The rise in chronic diseases is driven by factors such as aging populations, lifestyle changes, inadequate healthcare access, and heightened environmental exposures. Heplisav-B is particularly important in managing chronic diseases, especially for individuals with weakened immune systems, as it provides a stronger and longer-lasting immune response against hepatitis B. For instance, in June 2024, the National Health Service (NHS), a U.K.-based government department, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is expected to support the growth of the Heplisav-B market.
A key trend in the Heplisav-B market is the development of innovative products, such as hepatitis B adjuvanted vaccines, aimed at providing stronger and longer-lasting immune responses. A hepatitis B adjuvanted vaccine includes an adjuvant that enhances the body’s immune response to the hepatitis B surface antigen, thereby improving the vaccine's efficacy, particularly in populations with weaker immune systems. For instance, in February 2023, Dynavax Technologies Corporation, a U.S.-based biopharmaceutical company, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Heplisav-B for marketing in Great Britain. This vaccine is intended for adults and is approved for active immunization against all known subtypes of the hepatitis B virus (HBV) in individuals aged 18 years and older. The approval was based on favorable safety and immunogenicity outcomes from three Phase 3 clinical trials. Heplisav-B combines the hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist adjuvant, CpG 1018, to enhance the immune response. Dynavax holds the global commercial rights to Heplisav-B.
Major companies operating in the heplisav-b market are Dynavax Technologies Corporation.
North America was the largest region in the heplisav-B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heplisav-b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heplisav-b market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the heplisav-b market by increasing costs associated with vaccine raw materials, adjuvant components, and specialized manufacturing equipment. These impacts are most evident in hospital procurement and large clinic vaccination programs, particularly in regions reliant on imported vaccine inputs. Higher tariffs may affect pricing negotiations and vaccine accessibility in some markets. However, tariffs are also encouraging domestic vaccine production and localized supply chains. This is supporting long term resilience and supply stability in adult immunization programs.
The heplisav-b market research report is one of a series of new reports that provides heplisav-b market statistics, including heplisav-b industry global market size, regional shares, competitors with a heplisav-b market share, detailed heplisav-b market segments, market trends and opportunities, and any further data you may need to thrive in the heplisav-b industry. This heplisav-b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Heplisav-B is a recombinant vaccine developed to protect adults aged 18 and older against hepatitis B. It contains hepatitis B surface antigen (HBsAg) along with an advanced adjuvant (1018) to boost the immune response. Given as a two-dose series within a month, Heplisav-B provides higher seroprotection rates and greater convenience than traditional three-dose vaccines, making it especially beneficial for high-risk individuals, including healthcare workers, those with chronic liver disease, or individuals with diabetes.
The primary types of Heplisav-B products include vaccines and combination vaccines. Vaccines are biological substances that offer immunity against specific infectious diseases by stimulating the immune system to recognize and combat pathogens. It is used for adult hepatitis B prevention, as well as for special populations, and is distributed through integrated delivery networks (IDNs), large clinics, retail pharmacies, and hospitals.
The heplisav-B market consists of sales of adjuvants, immunology products, diagnostic kits, and therapeutic vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Heplisav-B Market Characteristics
3. Heplisav-B Market Supply Chain Analysis
4. Global Heplisav-B Market Trends and Strategies
5. Heplisav-B Market Analysis of End Use Industries
7. Global Heplisav-B Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Heplisav-B Total Addressable Market (TAM) Analysis for the Market
9. Heplisav-B Market Segmentation
10. Heplisav-B Market Regional and Country Analysis
11. Asia-Pacific Heplisav-B Market
12. China Heplisav-B Market
13. India Heplisav-B Market
14. Japan Heplisav-B Market
15. Australia Heplisav-B Market
16. South Korea Heplisav-B Market
17. Western Europe Heplisav-B Market
18. UK Heplisav-B Market
19. Germany Heplisav-B Market
20. France Heplisav-B Market
21. Eastern Europe Heplisav-B Market
22. North America Heplisav-B Market
23. USA Heplisav-B Market
24. Canada Heplisav-B Market
25. South America Heplisav-B Market
26. Middle East Heplisav-B Market
27. Africa Heplisav-B Market
29. Heplisav-B Market Competitive Landscape and Company Profiles
32. Heplisav-B Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Heplisav-B Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses heplisav-b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for heplisav-b? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The heplisav-b market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Vaccines; Combination Vaccines2) By Indication: Adult Hepatitis B Prevention; Special Populations
3) By Distribution Channel: Integrated Delivery Networks (IDNs) And Large Clinics; Retail Pharmacies; Hospitals
Companies Mentioned: Dynavax Technologies Corporation
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Heplisav-B market report include:- Dynavax Technologies Corporation
